Per Gryback
Overview
Explore the profile of Per Gryback including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Fransson S, Sundquist F, Nilsson J, Gryback P, Wessman S, et al.
Front Oncol
. 2024 Sep;
14:1408729.
PMID: 39324010
In this case report, we present the treatment outcomes of the first patient enrolled in the LuDO-N trial. The patient is a 21-month-old girl diagnosed with high-risk neuroblastoma (NB) and...
2.
Lagebro V, Piersiala K, Petro M, Lapins J, Gryback P, Margolin G, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444407
Cutaneous squamous cell cancer (cSCC) is the second most common form of skin cancer, characterized by abnormal, accelerated growth of squamous cells. When caught early, most cSCCs are curable. About...
3.
Nilsson J, Gryback P, Juhlin C, Hedman C, Ihre Lundgren C
Endocrine
. 2023 Jun;
82(2):343-352.
PMID: 37284971
Purpose: Patients with persistent or recurrent papillary and poorly differentiated thyroid cancer can be effectively treated with radioiodine, if the tumour tissue is iodine-avid. However, iodine-avidity status is often unknown...
4.
Bark R, Kolev A, Elliot A, Piersiala K, Nasman A, Gryback P, et al.
Cancer Med
. 2023 Apr;
12(11):12524-12534.
PMID: 37084007
Background: Sentinel lymph node biopsy (SLNB) is used to improve the staging of and guide treatment in patients with early-stage T1-T2 N0 oral squamous cell carcinoma (OSCC). The role of...
5.
Matikas A, Johansson H, Gryback P, Bjohle J, Acs B, Boyaci C, et al.
Clin Cancer Res
. 2022 Nov;
29(3):532-540.
PMID: 36449695
Purpose: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response...
6.
Sandqvist P, Sundin A, Nilsson I, Gryback P, Sanchez-Crespo A
Eur J Endocrinol
. 2022 Jun;
187(2):257-263.
PMID: 35666799
Objective: Successful preoperative image localisation of all parathyroid adenomas (PTA) in patients with primary hyperparathyroidism (pHPT) and multiglandular disease (MGD) remains challenging. We investigate whether a machine learning classifier (MLC)...
7.
Sundquist F, Georgantzi K, Brunsvig Jarvis K, Brok J, Koskenvuo M, Rascon J, et al.
Front Pediatr
. 2022 Apr;
10:836230.
PMID: 35359899
Background: Half the children with high-risk neuroblastoma die with widespread metastases. Molecular radiotherapy is an attractive systemic treatment for this relatively radiosensitive tumor. I-mIBG is the most widely used form...
8.
Hatschek T, Foukakis T, Bjohle J, Lekberg T, Fredholm H, Elinder E, et al.
JAMA Oncol
. 2021 Jun;
7(9):1360-1367.
PMID: 34165503
Importance: Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far...
9.
Sandqvist P, Farnebo J, Nilsson I, Gryback P, Sundin A, Sanchez-Crespo A
Insights Imaging
. 2021 Jun;
12(1):72.
PMID: 34091801
Objectives: To investigate the incremental value of Sestamibi SPECT combined with a non-enhanced and contrast-enhanced CT, using SPECT/CT, for the preoperative localisation of small parathyroid adenomas (PTA). Methods: Retrospectively, 147...
10.
Back A, Savvopoulos C, Kero T, Gryback P, Geijer H
Nucl Med Commun
. 2020 Sep;
41(10):1018-1025.
PMID: 32925827
Objective: The F+10 method for diuretic renography (diuretics given 10 min after the radiopharmaceutical) could be a time-conserving method. This method involves a 30-min dynamic acquisition where diuretics are administered...